President Trump may have used the bully pulpit to force Pfizer (PFE) to roll back a bunch of price hikes last July, but the drug maker now expects “business as normal” once January rolls around.

In an earnings conference call, Pfizer Chief Executive Officer Ian Read was asked about pricing going forward because the Trump administration has floated a few ideas to combat high costs, but taken little action. And so, Wall Street has been expecting drug companies — nearly all of which also hit the pause button on price hikes this past summer — will likely revert to their normal practice of raising prices each Jan. 1.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy